Starpharma Holdings Target Price for 2026

Starpharma Holdings

ASX:SPL

$ 0,52

+ $0,01 (1,96%)

0,52 $

+$0,01 (1,96%)

End-of-day quote: 04/10/2026

Starpharma Holdings Stock Value

According to analysts, the current valuation of ASX:SPL is Buy.

Buy

Starpharma Holdings Company Info

EPS Growth 5Y

7,79%

Market Cap

$0,22 B

Long-Term Debt

$0,00 B

Quarterly earnings

05/26/2026 (E)

Dividend

$0,00

Dividend Yield

0,00%

Founded

1997

Industry

Health Care

Country

Australia

Website

Starpharma Holdings

ISIN Number

AU000000SPL0

Website

http://starpharma.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

$0,80

53.85%

Last Update: 04/11/2026

Analysts: 1

Highest Price Target $0,80

Average Price Target $0,80

Lowest Price Target $0,80

In the last five quarters, Starpharma Holdings’s Price Target has risen from $0,95 to $0,95 - a 0,00% increase. One analysts predict that Starpharma Holdings’s share price will increase in the coming year, reaching $0,80. This would represent an increase of 53,85%.

Top growth stocks in the health care sector (5Y.)

What does Starpharma Holdings do?

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications worldwide. The company focuses on developing proprietary products based on its unique dendrimer technology platform. It specializes in creating new vaccines, drug delivery solutions, and antiviral and antimicrobial agents designed to improve therapeutic outcomes and patient care. Business Segments Th...

Business Segments

The company operates primarily through three major business segments: Pharmaceuticals, Drug Delivery, and Contract Services.

Pharmaceuticals

The Pharmaceuticals segment engages in developing and commercializing pharmaceutical products that utilize the company's dendrimer technology. This segment focuses on creating drugs in various therapeutic areas including oncology.

Drug Delivery

The Drug Delivery segment explores the application of dendrimer technology to enhance the delivery of existing drugs, offering improved absorption and reduced toxicity. This technology is particularly beneficial for administering biologics and poorly soluble compounds, and it has been employed in multiple clinical programs.

Contract Services

The Contract Services segment involves offering various services related to drug discovery and development that utilize the company's expertise in dendrimer technology. This segment provides critical laboratory services, including formulation development, analytical testing, and regulatory support.

Business Strategy

The company's business strategy emphasizes maximizing the potential of its dendrimer technology while building strategic partnerships to facilitate growth and product development. The company aims to focus on developing its proprietary products, enhancing existing therapeutic agents, and exploring new applications for its technology.

The strategy includes prioritizing research and development for existing drug candidates to bring them closer to commercialization. Collaborations with other biotechnology and pharmaceutical companies are central to this strategy; by leveraging partnerships, the company can accelerate the development process and access broader markets.

Additionally, the company is committed to expanding its international reach. By increasing its presence in global markets, the company aims to establish itself as a leading player in biotechnology.

Products and Services

The company’s portfolio is driven by its proprietary dendrimer technology, which serves as the foundation for its products. Key offerings include:

Dendrimer-based Pharmaceuticals: The company develops a range of dendrimer-based drugs targeting various diseases, primarily focusing on oncology.

Vaccine Development: The company engages in creating novel vaccine candidates using its dendrimer technology to generate robust immunogenic responses.

Antiviral and Antimicrobial Agents: Dendrimer technology also extends to the development of antiviral and antimicrobial products.

Contract Research Services: The company provides laboratory services that include drug formulation and testing, analytical development, and assistance with the regulatory process.

Collaborative Research Projects: The company participates in collaborations that focus on developing drug delivery systems and enhancing the performance of existing pharmaceutical compounds.

Geographical Markets Served

The company serves a diverse array of geographical markets. Its primary focus is on the Australian biotechnology market, where it has established its foundational presence. The company is also active in expanding its reach into international markets, including North America, Europe, and Asia-Pacific regions.

Seasonality

The company experiences minimal seasonality in its operations. Research timelines and clinical trials dictate operational schedules more than market fluctuations, making the company's financial performance relatively stable throughout the year.

Customers

The company serves a wide array of customers, primarily in the pharmaceutical and biotechnology sectors. Major customers include large pharmaceutical companies with which the company collaborates on drug development projects. The customer base extends across several categories, including academic institutions, government research bodies, and health organizations engaged in biomedical research.

Sales and Marketing

The company employs a multifaceted approach to marketing and sales, largely focusing on B2B interactions within the biotechnology and pharmaceutical sectors. The marketing strategy includes leveraging scientific research and showcasing clinical data to attract partnerships and collaborations. Distribution channels primarily align with contract services and partnerships rather than traditional retail pathways, allowing for targeted engagements with potential clients, including pharmaceutical manufacturers and research institutions.

Government Regulations

The company operates under strict government regulations specific to the biotechnology and pharmaceutical industries in Australia. Compliance includes adherence to regulations set forth by the Therapeutic Goods Administration (TGA) for the approval and marketing of pharmaceuticals and medical devices.

History

Starpharma Holdings Limited was incorporated in 1997.

New support ticket

Explore

Starpharma Holdings Stock Value

Starpharma Holdings Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Starpharma Holdings do?

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Starpharma Holdings Stock Value

Starpharma Holdings Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Starpharma Holdings do?

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.